Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: Associations with presenting features, serum interleukin 10 levels, and clinical outcome

Clinical Cancer Research

Volumn 9, Issue 6, 2003, Pages 2114-2120

  Herling, Marco ^a   Rassidakis, George Z ^a   Medeiros, L Jeffrey ^a   Vassilakopoulos, Theodoros P ^d   Kliche, Kay Oliver ^a   Nadali, Gianpaolo ^c   Viviani, Simonetta ^b   Bonfante, Valeria ^b   Giardini, Roberto ^b   Chilosi, Marco ^c   Kittas, Christos ^d   Gianni, Alessandro M ^b   Bonadonna, Gianni ^b   Pizzolo, Giovanni ^c   Pangalis, Gerassimos A ^d   Cabanillas, Fernando ^a   Sarris, Andreas H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; INTERLEUKIN 10; LACTATE DEHYDROGENASE; LATENT MEMBRANE PROTEIN 1; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BIOPSY; BONE MARROW; CANCER REGRESSION; CANCER SURVIVAL; CELL TYPE; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; TREATMENT FAILURE;

ADULT; AGED; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; MALE; MIDDLE AGED; REED-STERNBERG CELLS; VIRAL MATRIX PROTEINS;

EID: 0037838706     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kanzler, H., Kuppers, R., Hansmann, M. L., and Rajewsky, K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med., 184: 1495-1505, 1996.
2. Kuppers, R., and Rajewsky, K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Ann. Rev. Immunol., 16: 471-493, 1998.
3. Marafioti, T., Hummel, M., Foss, H. D., Laumen, H., Korbjuhn, P., Anagnostopoulos, I., Lammert, H., Demel, G., Theil, J., Wirth, T., and Stein, H. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood, 95: 1443-1450, 2000.
4. Stein, H., Marafioti, T., Foss, H. D., Laumen, H., Hummel, M., Anagnostopoulos, I., Wirth, T., Demel, G., and Falini, B. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood, 97: 496-501, 2001.
5. Herbst, H., Foss, H-D., Samol, J., Araujo, I., Klotzbach, H., Krause, H., Agathanggelou, A., Niedobitek, G., and Stein, H. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood, 87: 2918-2929, 1996.
6. Ohshima, K., Suzumiya, J., Akamatu, M., Takeshita, M., and Kikuchi, M. Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int. J. Cancer, 62: 5-10, 1995.
7. Ambinder, R. F., Lemas, M. V., Moore, S., Yang, J., Fabian, D., and Krone, C. Epstein-Barr virus and lymphoma. Cancer Treat. Res., 99: 27-45, 1999.
8. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E., and Rickinson, A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65: 1107-1115, 1991.
9. Gregory, C. D., Dive, C., Henderson, S., Smith, C. A., Williams, G. T., Gordon, J., and Rickinson, A. B. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (Lond.), 349: 612-614, 1991.
10. Wang, S., Rowe, M., and Lundgren, E. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-I levels in B-cell lines. Cancer Res., 56: 4610-4613, 1996.
11. Dukers, D. F., Jaspars, L. H., Vos, W., Oudejans, J. J., Hayes, D., Cillessen, S., Middeldorp, J. M., and Meijer, C. J. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J. Pathol., 190: 143-149, 2000.
12. Rassidakis, G., Medeiros, L. J., Nadali, G., Viviani, S., Bonfante, V., Vassilakopoulos, T., Kolbe, E., Gansbacher, B., Kunkel, S., Giardini, R., Chilosi, M., Kittas, C., Bonnadona, G., Gianni, A. M., Pizzolo, G., Pangalis, G. A., Cabanillas, F., and Sarris, A. Expression of interleukin-10 (IL-10) in Hodgkin's disease (HD): pathologic and clinical associations. Blood, 98 (Part 1): 2511, 2001.
13. Wang, L., Goillot, E., and Tepper, R. I. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell. Immunol., 159: 152-169, 1994.
14. Suzuki, T., Tahara, H., Narula, S., Moore, K. W., Robbins, P. D., and Lotze, M. T. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J. Exp. Med., 182: 477-486, 1995.
15. Levy, Y., and Brouet, J. C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Investig., 93: 424-428, 1994.
16. Sarris, A. H., Kliche, K. O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F. B., McLaughlin, P., Rodriguez, M. A., Romaguera, J., Fritsche, H., Witzig, T., Duvic, M., Andreeff, M., and Cabanillas, F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol., 10: 433-440, 1999.
17. Bohlen, H., Kessler, M., Sextro, M., Diehl, V., and Tesch, H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann. Hematol., 79: 110-113, 2000.
18. Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Siakantaris, M. P., Dimopoulou, M. N., Kontopidou, F. N., Rassidakis, G. Z., Doussis-Anagnostopoulou, I. A., Hatzioannou, M., Vaiopoulos, G., Kittas, C., Sarris, A. H., Pizzolo, G., and Pangalis, G. A. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica, 86: 274-281, 2001.
19. Axdorph, U., Sjoberg, J., Grimfors, G., Landgren, O., Porwit-MacDonald, A., and Bjorkholm, M. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann. Oncol., 11: 1405-1411, 2000.
20. Taga, K., Chretien, J., Cherney, B., Diaz, L., Brown, M., and Tosato, G. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J. Clin. Investig., 94: 251-260, 1994.
21. + hematopoietic progenitor cells. Blood, 88: 2549-2558, 1996.
22. Brunetti, M., Martelli, N., Colasante, A., Piantelli, M., Musiani, P., and Aiello, F. B. Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes. Blood, 86: 4199-4205, 1995.
23. Stein, H., Mann, R., Delsol, G., Poppema, S., Pileri, S., Jaffe, E., Said, J. W., and Sherdlow, S. Classical Hodgkin lymphoma, pathology and genetics. In: E. Jaffe, N. Harris, H. Stein, and J. Vardiman (eds.), World Health Organization Classification of Tumours, pp. 244-253. Lyon, France: IARC Press, 2001.
24. Rassidakis, G. Z., Medeiros, L. J., Viviani, S., Bonfante, V., Nadali, G. P., Vassilakopoulos, T. P., Mesina, O., Herling, M., Angelopoulou, M. K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M. A., Romaguera, J., Bonadonna, G., Gianni, A. M., Pizzolo, G., Pangalis, G. A., Cabanillas, F., and Sarris, A. H. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Disease: associations with presenting features and clinical outcome. J. Clin. Oncol., 20: 1278-1287, 2002.
25. Rassidakis, G. Z., Medeiros, L. J., McDonnell, T. J., Viviani, S., Bonfante, V., Nadali, G., Vassilakopoulos, T. P., Giardini, R., Chilosi, M., Kittas, C., Gianni, A. M., Bonadonna, G., Pizzolo, G., Pangalis, G. A., Cabanillas, F., and Sarris, A. H. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin. Cancer Res., 8: 488-493, 2002.
26. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., and Peterson, B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med., 327: 1478-1484, 1992.
27. Miller, G., Shope, T., Lisco, H., Stitt, D., and Lipman, M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. USA, 69: 383-387, 1972.
28. Kaplan, E. L., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 257-481, 1958.
29. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
30. Cox, D. R. Regression models and life tables (with discussion). J. R. Stat. Soc. B, 34: 187-220, 1972.
31. Hagemeister, F. B., Fuller, L., McLaughlin, P., Rodriguez, M., Romaguera, J., Swan, F., and Cabanillas, F. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann. Oncol., 4: 87-90, 1992.
32. Longo, D. L., Young, R. C., Wesley, M., Hubbard, S. M., Duffey, P. L., Jaffe, E. S., and De Vita, V. T., Jr. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol., 4: 1295-1306, 1986.
33. Ambinder, R. F., Browning, P. J., Lorenzana, I., Leventhal, B. G., Cosenza, H., Mann, R. B., MacMahon, E. M., Medina, R., Cardona, V., Grufferman, S., et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood, 81: 462-467, 1993.
34. Zhou, X. G., Sandvej, K., Li, P. J., Ji, X. L., Yan, Q. H., Zhang, X. P., Da, J. P., and Hamilton-Dutoit, S. J. Epstein-Barr virus (EBV) in Chinese pediatric Hodgkin disease: Hodgkin disease in young children is an EBV-related lymphoma. Cancer (Phila.), 92: 1621-1631, 2001.
35. Carde, P. Hodgkin's disease. Diagnostic procedures. Baillieres Clin. Haematol., 9: 479-501, 1996.
36. Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Siakantaris, M. P., Dimopoulou, M. N., Kontopidou, F. N., Karkantaris, C., Kokoris, S. I., Kyrtsonis, M. C., Tsaftaridis, P., Pizzolo, G., and Pangalis, G. A. The prognostic significance of β2-microglobulin in patients with Hodgkin's lymphoma. Haematologica, 87: 701-708, 2002.
37. Morente, M. M., Piris, M. A., Abraira, V., Acevedo, A., Aguilera, B., Bellas, C., Fraga, M., Garcia-Del-Moral, R., Gomez-Marcos, F., Menarguez, J., Oliva, H., Sanchez-Beato, M., and Montalban, C. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood, 90: 2429-2436, 1997.
38. Murray, P. G., Billingham, L. J., Hassan, H. T., Flavell, J. R., Nelson, P. N., Scott, K., Reynolds, G., Constandinou, C. M., Kerr, D. J., Devey, E. C., Crocker, J., and Young, L. S. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood, 94: 442-447, 1999.
39. Enblad, G., Sandvej, K., Sundstrom, C., Pallesen, G., and Glimelius, B. Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncol., 38: 425-429, 1999.
40. Naresh, K. N., Johnson, J., Srinivas, V., Soman, C. S., Saikia, T., Advani, S. H., Badwe, R. A., Dinshaw, K. A., Muckaden, M., Magrath, I., and Bhatia, K. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells. Ann. Oncol., 11: 91-96, 2000.
41. Glavina-Durdov, M., Jakic-Razumovic, J., Capkun, V., and Murray, P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br. J. Cancer, 84: 1227-1234, 2001.
42. Clarke, C. A., Glaser, S. L., Dorfman, R. F., Mann, R., DiGiuseppe, J. A., Prehn, A. W., and Ambinder, R. F. Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer (Phila.), 91: 1579-1587, 2001.
43. Vassallo, J., Metze, K., Traina, F., de Souza, C. A., and Lorand-Metze, I. Expression of Epstein-Barr virus in classical Hodgkin's lymphomas in Brazilian adult patients. Haematologica, 86: 1227-1228, 2001.
44. Khanim, F., Yao, Q. Y., Niedobitek, G., Sihota, S., Rickinson, A. B., and Young, L. S. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood, 88: 3491-3501, 1996.
45. Sandvej, K., Andresen, B. S., Zhou, X. G., Gregersen, N., and Hamilton-Dutoit, S. Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site. Mol. Pathol., 53: 280-288, 2000.
46. Knecht, H., Bachmann, E., Brousset, P., Sandvej, K., Nadal, D., Bachmann, F., Odermatt, B. F., Delsol, G., and Pallesen, G. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood, 82: 2937-2942, 1993.
47. Rooney, C. M., Roskrow, M. A., Suzuki, N., Ng, C. Y., Brenner, M. K., and Heslop, H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann. Oncol., 9: S129-S132, 1998.
48. Kenney, J. L., Guinness, M. E., Curiel, T., and Lacy, J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood, 92: 1721-1727, 1998.
49. Guinness, M. E., Kenney, J. L., Reiss, M., and Lacy, J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res., 60: 5354-5358, 2000.